Swiss biotech VERAXA lands on NASDAQ via Voyager SPAC merger
What's the deal? Swiss biotechnology company VERAXA BiotechDealroom has a profile for this one. Try Dealroom → began trading on the NASDAQ Capital Market under the ticker VRXA in June 2026, following its completed merger with Voyager Acquisition CorpDealroom has a profile for this one. Try Dealroom →. The transaction gives VERAXADealroom has a profile for this one. Try Dealroom → access to the US public markets as it develops its oncology pipeline. Deal value was not disclosed.
What's the endgame? VERAXA is building an oncology pipeline around its proprietary BiTAC platform, alongside antibody-drug conjugate and engineered-antibody technologies. BiTAC uses an "AND-gated" design, in which two complementary components must both engage the same cancer cell before the intended cytotoxic mechanism activates.
What's the science so far? The company has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches. That includes an in-vitro proof of concept for BiTAC-ADC announced in June.
The financing: The merger came with financing arrangements including a $27.5 million senior secured note and a securities purchase agreement.
Who's steering it? VERAXA appointed Raju Willener as chief financial officer and Christoph Erkel, Ph.D., as chief scientific officer, adding financial and antibody-development expertise as the company enters its public-market phase.
What could go wrong? VERAXA's programs remain preclinical, meaning years of clinical trials stand between the platform and any approved therapy. The company itself flags risks tied to development and its reliance on capital as a newly public firm.
The signal: SPAC mergers remain a route for early-stage biotechs to reach public markets without a traditional IPO. For VERAXA, the NASDAQ listing and attached financing buy time to prove the BiTAC platform can move from the lab toward the clinic.
Image credit: NYTVF
